Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | Evaluating the efficacy of ixazomib, cyclophosphamide and dexamethasone in amyloidosis

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses a Phase II trial evaluating the safety and efficacy of ixazomib in combination with cyclophosphamide and dexamethasone in the treatment of light chain (AL) amyloidosis. Results demonstrated that the ixazomib combination can effectively control disease, however, the small size of the study and the growing use of daratumumab may limit the role of this combination in clinical practice. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research funding for clinical trials to the institution: Abbvie, Amgen, Allogene, BMS, Carsgen, GSK, Janssen, Roche-Genentech, Takeda, Regeneron
Consulting/Advisory Board participation: (with no personal payments) Abbvie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, Beigene, and (with personal payment) Oncopeptides, Antengene